Blood
Articles in this Issue
Smarter combos, stronger T cells in lymphoma
Treatment of relapsed and refractory follicular lymphoma: which treatment for which patient for which line of therapy?
Abstract Recent advances have transformed the treatment landscape for relapsed and refractory follicular lymphoma. Although chemotherapy has long served as the backbone of treatment,...
T-large granular lymphocytic leukemia transformation to peripheral T-cell lymphoma
Induction chemotherapy and molecular MRD influence outcomes in <i>KMT2A</i> -rearranged AML
Abstract We analyzed 217 patients with KMT2A-rearranged acute myeloid leukemia (AML) in 2 large sequential randomized trials. Those randomized to FLAG-Ida (fludarabine, cytarabine,...
A rare case of epithelioid hemangioendothelioma involving bone marrow
Unlocking myeloma's spatial world at the micrometer scale
End points and outcomes in follicular lymphoma: what should we measure, how, and why?
Abstract Overall survival (OS) and quality of life (QoL) are clinically relevant outcomes/end points during examination of therapies. However, with median OS approaching 20 years for...
The future of follicular lymphoma management: strategies on the horizon
Abstract Progress in the therapy of follicular lymphoma (FL), the most common indolent lymphoma subtype, has been achieved in recent years with significant improvement in median over...
Profiling the spatial architecture of multiple myeloma in human bone marrow trephine biopsy specimens with spatial transcriptomics
Abstract The bone marrow microenvironment is intimately linked to the biology that underpins the development and progression of multiple myeloma. However, the complex cellular and mo...
Mel200 or BuMel conditioning in myeloma: is there a winner?
Preclinical advances in glofitamab combinations: a new frontier for non-Hodgkin lymphoma
Abstract T-cell engagers (TCEs) are transformative therapeutics in hematologic malignancies, including non-Hodgkin lymphoma. Initially approved for relapsed/refractory disease settin...
High-dose busulfan-melphalan vs melphalan and reinforced VRD for newly diagnosed multiple myeloma: a phase 3 GEM trial
Abstract In retrospective studies, autologous stem cell transplantation (ASCT) conditioning with intravenous busulfan and melphalan (BUMEL) led to longer progression-free survival (P...
Plasminogen as a ribonucleoprotein: regulatory small RNA cargo modulates fibrinolysis and inflammation
Abstract Cell-free RNA (cf-RNA) has emerged as a critical mediator of intercellular communication and a potential regulator of hemostasis. In this study, plasminogen (Plg), the zymog...
Frontline treatment of follicular lymphoma: what will it take to change current practice?
Abstract Follicular lymphoma is the most common subtype of indolent lymphoma. Despite multiple trials over the past decades showing improved progression-free survival with new first-...
An updated understanding of follicular lymphoma transformation
Abstract Although most patients with follicular lymphoma (FL) follow an indolent disease course, some patients experience a critical inflection point when FL transforms into an aggre...
Introduction to a review series on follicular lymphoma: solved or insoluble problem?
Although there have been many therapeutic advances in follicular lymphoma (FL) in recent years, important questions remain about how best to integrate emerging biologic insights with evolving treatmen...
Biology as vulnerability in follicular lymphoma: genetics, epigenetics, and immunogenetics
Abstract Follicular lymphoma (FL) represents a heterogeneous group of B-cell neoplasms with distinct genetic, epigenetic, microenvironmental, and clinical features. It is the most pr...